Publications by authors named "Danielle Dupont"

Claim this Profile
R
Reevaluating health metrics: Unraveling the limitations of disability-adjusted life years as an indicator in disease burden assessment.
Ariel Beresniak, Dominique Bremond-Gignac, Danielle Dupont, Gerard Duru

World J Methodol· March 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
The FLURESP European commission project: cost-effectiveness assessment of ten public health measures against influenza in Italy: is there an interest in COVID-19 pandemic?
Ariel Beresniak, Christian Napoli, John Oxford, Alejandra Daruich, Laurent Niddam, Danielle Dupont

Cost Eff Resour Alloc· May 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
[
[Value of hospital electronic health records for clinical research: contribution of the European project EHR4CR].
Danielle Dupont, Ariel Beresniak, Dipak Kalra, Pascal Coorevits, Georges De Moor

Med Sci (Paris)· November 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Business analysis for a sustainable, multi-stakeholder ecosystem for leveraging the Electronic Health Records for Clinical Research (EHR4CR) platform in Europe.
Danielle Dupont, Ariel Beresniak, Mats Sundgren, Andreas Schmidt, John Ainsworth

Int J Med Inform· January 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Improving Performance of Clinical Research: Development and Interest of Electronic Health Records.
Ariel Beresniak, Andreas Schmidt, Danielle Dupont, Mats Sundgren, Dipak Kalra

Biomed Res Int· August 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Impact of pigmentary disorders on quality of life in Japan: Interest of the BeautyQoL instrument.
Ariel Beresniak, Jean-Paul Auray, Gérard Duru, Selim Aractingi, Gerald G Krueger, Danielle Dupont

J Cosmet Laser Ther· July 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Is there an alternative to quality-adjusted life years for supporting healthcare decision making?
Ariel Beresniak, Danielle Dupont

Expert Rev Pharmacoecon Outcomes Res· June 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-benefit assessment of using electronic health records data for clinical research versus current practices: Contribution of the Electronic Health Records for Clinical Research (EHR4CR) European Project.
Ariel Beresniak, Andreas Schmidt, Johann Proeve, Elena Bolanos, Neelam Patel, Danielle Dupont

Contemp Clin Trials· January 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
Q
Quality of life assessment in cosmetics: specificity and interest of the international BeautyQol instrument.
Ariel Beresniak, Jean-Paul Auray, Gérard Duru, Selim Aractingi, Gerald G Krueger, Danielle Dupont

J Cosmet Dermatol· September 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Using electronic health records for clinical research: the case of the EHR4CR project.
Georges De Moor, Mats Sundgren, Dipak Kalra, Andreas Schmidt, Martin Dugas, Danielle Dupont

J Biomed Inform· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
V
Validation of the underlying assumptions of the quality-adjusted life-years outcome: results from the ECHOUTCOME European project.
Ariel Beresniak, Antonieta Medina-Lara, Jean Paul Auray, Alain De Wever, Jean-Claude Praet, Danielle Dupont

Pharmacoeconomics· January 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness simulation model of biologic strategies for treating to target rheumatoid arthritis in Germany.
Ariel Beresniak, Christoph Baerwald, Henning Zeidler, Klaus Krüger, Aljoscha S Neubauer, Danielle Dupont

Clin Exp Rheumatol· August 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Interest of modelling in rheumatoid arthritis.
Ariel Beresniak, Danielle M Dupont, Jean-Claude Becker, Sonja Merkesdal

Clin Exp Rheumatol· March 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Modelling cost-effectiveness of biologic treatments based on disease activity scores for the management of rheumatoid arthritis in Spain.
Ariel Beresniak, Rafael Ariza-Ariza, Jose Francisco Garcia-Llorente, Antonio Ramirez-Arellano, Danielle Dupont

Int J Inflam· November 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Direct cost-modeling of rheumatoid arthritis according to disease activity categories in France.
Ariel Beresniak, Laure Gossec, Philippe Goupille, Alain Saraux, Marion Bamberger, Danielle Dupont

J Rheumatol· March 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness modelling of biological treatment sequences in moderate to severe rheumatoid arthritis in France.
Alain Saraux, Laure Gossec, Philippe Goupille, Bruno Bregman, Eric Boccard, Danielle Dupont

Rheumatology (Oxford)· April 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Cost-effectiveness modeling of abatacept versus other biologic agents in DMARDS and anti-TNF inadequate responders for the management of moderate to severe rheumatoid arthritis.
Anthony Russell, Ariel Beresniak, Louis Bessette, Boulos Haraoui, Proton Rahman, Danielle Dupont

Clin Rheumatol· April 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis